Drugs interactions for

  • 446 Major drug interactions (including ingredients like Abametapir, Abatacept, Acalabrutinib)
  • 431 Moderate drug interactions (including ingredients like Abemaciclib, Acyclovir, Alendronic acid)
  • 343 Minor drug interactions (including ingredients like Abacavir, Abiraterone, Abrocitinib)
1220 interactions for
A therapy excluded from this list of known interactions does not necessarily mean that no interactions exist between that therapy and and .
Abametapir
The serum concentration of Pomalidomide can be increased when it is combined with Abametapir.
Abatacept
The metabolism of Pomalidomide can be increased when combined with Abatacept.
Acalabrutinib
The metabolism of Pomalidomide can be decreased when combined with Acalabrutinib.
Acenocoumarol
The metabolism of Pomalidomide can be decreased when combined with Acenocoumarol.
Acetaminophen
The metabolism of Pomalidomide can be increased when combined with Acetaminophen.
Acetazolamide
The serum concentration of Pomalidomide can be increased when it is combined with Acetazolamide.
Adagrasib
The serum concentration of Pomalidomide can be increased when it is combined with Adagrasib.
Adalimumab
The metabolism of Pomalidomide can be increased when combined with Adalimumab.
Adenovirus type 7 vaccine live
The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Pomalidomide.
Afatinib
The serum concentration of Pomalidomide can be increased when it is combined with Afatinib.
Albendazole
The metabolism of Pomalidomide can be increased when combined with Albendazole.
Aldesleukin
The serum concentration of Pomalidomide can be increased when it is combined with Aldesleukin.
Alemtuzumab
The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pomalidomide.
Alosetron
The metabolism of Pomalidomide can be decreased when combined with Alosetron.
Alpelisib
The metabolism of Pomalidomide can be increased when combined with Alpelisib.
Aminophylline
The metabolism of Pomalidomide can be decreased when combined with Aminophylline.
Amlodipine
The metabolism of Pomalidomide can be decreased when combined with Amlodipine.
Amobarbital
The metabolism of Pomalidomide can be increased when combined with Amobarbital.
Anagrelide
The metabolism of Pomalidomide can be decreased when combined with Anagrelide.
Anakinra
The metabolism of Pomalidomide can be increased when combined with Anakinra.
Anifrolumab
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Anifrolumab.
Antilymphocyte immunoglobulin (horse)
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Antilymphocyte immunoglobulin (horse).
Antithymocyte immunoglobulin (rabbit)
The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pomalidomide.
Apremilast
The metabolism of Pomalidomide can be increased when combined with Apremilast.
Aprepitant
The metabolism of Pomalidomide can be decreased when combined with Aprepitant.
Arsenic trioxide
The serum concentration of Pomalidomide can be increased when it is combined with Arsenic trioxide.
Asunaprevir
The serum concentration of Pomalidomide can be increased when it is combined with Asunaprevir.
Atazanavir
The metabolism of Pomalidomide can be decreased when combined with Atazanavir.
Avacincaptad pegol
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Avacincaptad pegol.
Avacopan
The serum concentration of Pomalidomide can be increased when it is combined with Avacopan.
Axitinib
The metabolism of Pomalidomide can be decreased when combined with Axitinib.
Azacitidine
The risk or severity of adverse effects can be increased when Azacitidine is combined with Pomalidomide.
Azathioprine
The risk or severity of adverse effects can be increased when Azathioprine is combined with Pomalidomide.
Azelastine
Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Bacillus calmette-guerin substrain tice live antigen
The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Pomalidomide.
Baricitinib
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Baricitinib.
Basiliximab
The risk or severity of adverse effects can be increased when Basiliximab is combined with Pomalidomide.
Beclomethasone dipropionate
The metabolism of Pomalidomide can be increased when combined with Beclomethasone dipropionate.
Belatacept
The risk or severity of adverse effects can be increased when Belatacept is combined with Pomalidomide.
Belimumab
The risk or severity of adverse effects can be increased when Belimumab is combined with Pomalidomide.
Belinostat
The risk or severity of adverse effects can be increased when Belinostat is combined with Pomalidomide.
Belumosudil
The serum concentration of Pomalidomide can be increased when it is combined with Belumosudil.
Bendamustine
The risk or severity of adverse effects can be increased when Bendamustine is combined with Pomalidomide.
Betamethasone
The metabolism of Pomalidomide can be increased when combined with Betamethasone.
Bexarotene
The metabolism of Pomalidomide can be increased when combined with Bexarotene.
Bicalutamide
The metabolism of Pomalidomide can be decreased when combined with Bicalutamide.
Bimekizumab
The metabolism of Pomalidomide can be increased when combined with Bimekizumab.
Binimetinib
The metabolism of Binimetinib can be decreased when combined with Pomalidomide.
Bleomycin
The risk or severity of adverse effects can be increased when Bleomycin is combined with Pomalidomide.
Blinatumomab
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Blinatumomab.
Bortezomib
The risk or severity of adverse effects can be increased when Bortezomib is combined with Pomalidomide.
Bosentan
The metabolism of Pomalidomide can be increased when combined with Bosentan.
Bosutinib
The metabolism of Pomalidomide can be decreased when combined with Bosutinib.
Brentuximab vedotin
The serum concentration of Pomalidomide can be increased when it is combined with Brentuximab vedotin.
Brodalumab
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Brodalumab.
Budesonide
The metabolism of Pomalidomide can be increased when combined with Budesonide.
Busulfan
The risk or severity of adverse effects can be increased when Busulfan is combined with Pomalidomide.
Butalbital
The metabolism of Pomalidomide can be increased when combined with Butalbital.
Cabazitaxel
The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pomalidomide.
Caffeine
The metabolism of Pomalidomide can be decreased when combined with Caffeine.
Calcitriol
The metabolism of Pomalidomide can be increased when combined with Calcitriol.
Canagliflozin
The serum concentration of Pomalidomide can be increased when it is combined with Canagliflozin.
Canakinumab
The metabolism of Pomalidomide can be increased when combined with Canakinumab.
Capecitabine
The risk or severity of adverse effects can be increased when Capecitabine is combined with Pomalidomide.
Carbamazepine
The metabolism of Pomalidomide can be increased when combined with Carbamazepine.
Carboplatin
The risk or severity of adverse effects can be increased when Carboplatin is combined with Pomalidomide.
Carfilzomib
The serum concentration of Pomalidomide can be increased when it is combined with Carfilzomib.
Carmustine
The risk or severity of adverse effects can be increased when Carmustine is combined with Pomalidomide.
Carvedilol
The serum concentration of Pomalidomide can be increased when it is combined with Carvedilol.
Ceritinib
The metabolism of Pomalidomide can be decreased when combined with Ceritinib.
Certolizumab pegol
The metabolism of Pomalidomide can be increased when combined with Certolizumab pegol.
Chikungunya vaccine (live, attenuated)
The risk or severity of infection can be increased when Chikungunya vaccine (live, attenuated) is combined with Pomalidomide.
Chlorambucil
The risk or severity of adverse effects can be increased when Chlorambucil is combined with Pomalidomide.
Chloramphenicol
The serum concentration of Pomalidomide can be increased when it is combined with Chloramphenicol.
Chlorpromazine
The metabolism of Pomalidomide can be increased when combined with Chlorpromazine.
Ciclesonide
The risk or severity of adverse effects can be increased when Ciclesonide is combined with Pomalidomide.
Cimetidine
The metabolism of Pomalidomide can be decreased when combined with Cimetidine.
Cisplatin
The risk or severity of adverse effects can be increased when Cisplatin is combined with Pomalidomide.
Citalopram
The metabolism of Pomalidomide can be decreased when combined with Citalopram.
Clarithromycin
The metabolism of Pomalidomide can be decreased when combined with Clarithromycin.
Clevidipine
The metabolism of Pomalidomide can be increased when combined with Clevidipine.
Clobetasol propionate
The metabolism of Pomalidomide can be increased when combined with Clobetasol propionate.
Clofarabine
The risk or severity of adverse effects can be increased when Clofarabine is combined with Pomalidomide.
Clomipramine
The metabolism of Pomalidomide can be decreased when combined with Clomipramine.
Clonidine
The risk or severity of sedation can be increased when Clonidine is combined with Pomalidomide.
Cobicistat
The serum concentration of Pomalidomide can be increased when it is combined with Cobicistat.
Conivaptan
The metabolism of Pomalidomide can be decreased when combined with Conivaptan.
Conjugated estrogens
The metabolism of Pomalidomide can be decreased when combined with Conjugated estrogens.
Corticotropin
The metabolism of Pomalidomide can be increased when combined with Corticotropin.
Cortisone acetate
The metabolism of Pomalidomide can be increased when combined with Cortisone acetate.
Crovalimab
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Crovalimab.
Curcumin
The metabolism of Pomalidomide can be decreased when combined with Curcumin.
Cyclophosphamide
The metabolism of Pomalidomide can be increased when combined with Cyclophosphamide.
Cyclosporine
Pomalidomide may increase the immunosuppressive activities of Cyclosporine.
Cytarabine
The risk or severity of adverse effects can be increased when Cytarabine is combined with Pomalidomide.
Dacarbazine
The risk or severity of adverse effects can be increased when Dacarbazine is combined with Pomalidomide.
Dacomitinib
The serum concentration of Pomalidomide can be increased when it is combined with Dacomitinib.
Dactinomycin
The risk or severity of adverse effects can be increased when Dactinomycin is combined with Pomalidomide.
Dalfopristin
The metabolism of Pomalidomide can be decreased when combined with Dalfopristin.
Danazol
The metabolism of Pomalidomide can be decreased when combined with Danazol.
Darunavir
The serum concentration of Pomalidomide can be increased when it is combined with Darunavir.
Dasatinib
The metabolism of Pomalidomide can be decreased when combined with Dasatinib.
Daunorubicin
The serum concentration of Pomalidomide can be increased when it is combined with Daunorubicin.
Decitabine
The risk or severity of adverse effects can be increased when Decitabine is combined with Pomalidomide.
Deflazacort
The metabolism of Pomalidomide can be increased when combined with Deflazacort.
Desipramine
The serum concentration of Pomalidomide can be increased when it is combined with Desipramine.
Desoximetasone
The risk or severity of adverse effects can be increased when Desoximetasone is combined with Pomalidomide.
Desvenlafaxine
The metabolism of Pomalidomide can be decreased when combined with Desvenlafaxine.
Deucravacitinib
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Deucravacitinib.
Dexamethasone
The metabolism of Pomalidomide can be increased when combined with Dexamethasone.
Dexamethasone acetate
The serum concentration of Pomalidomide can be decreased when it is combined with Dexamethasone acetate.
Dexmedetomidine
The metabolism of Pomalidomide can be decreased when combined with Dexmedetomidine.
Dexrazoxane
The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Pomalidomide.
Dextropropoxyphene
The serum concentration of Pomalidomide can be increased when it is combined with Dextropropoxyphene.
Diazoxide
The metabolism of Pomalidomide can be decreased when combined with Diazoxide.
Dicloxacillin
The metabolism of Pomalidomide can be increased when combined with Dicloxacillin.
Dihydroergotamine
The serum concentration of Pomalidomide can be increased when it is combined with Dihydroergotamine.
Diltiazem
The metabolism of Pomalidomide can be decreased when combined with Diltiazem.
Dimethyl fumarate
The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Pomalidomide.
Dimethyl sulfoxide
The serum concentration of Pomalidomide can be increased when it is combined with Dimethyl sulfoxide.
Dinutuximab
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Dinutuximab.
Diosmin
The serum concentration of Pomalidomide can be increased when it is combined with Diosmin.
Diroximel fumarate
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Diroximel fumarate.
Docetaxel
The serum concentration of Pomalidomide can be increased when it is combined with Docetaxel.
Doxorubicin
The serum concentration of Pomalidomide can be increased when it is combined with Doxorubicin.
Echinacea
The metabolism of Pomalidomide can be increased when combined with Echinacea.
Eculizumab
The risk or severity of adverse effects can be increased when Eculizumab is combined with Pomalidomide.
Efavirenz
The metabolism of Pomalidomide can be decreased when combined with Efavirenz.
Efgartigimod alfa
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Efgartigimod alfa.
Elafibranor
The metabolism of Pomalidomide can be increased when combined with Elafibranor.
Elagolix
The serum concentration of Pomalidomide can be increased when it is combined with Elagolix.
Elvitegravir
The metabolism of Pomalidomide can be decreased when combined with Elvitegravir.
Emapalumab
The metabolism of Pomalidomide can be increased when combined with Emapalumab.
Enasidenib
The serum concentration of Pomalidomide can be increased when it is combined with Enasidenib.
Encorafenib
The serum concentration of Pomalidomide can be increased when it is combined with Encorafenib.
Entrectinib
The serum concentration of Pomalidomide can be increased when it is combined with Entrectinib.
Epinephrine
The serum concentration of Pomalidomide can be increased when it is combined with Epinephrine.
Epirubicin
The risk or severity of adverse effects can be increased when Epirubicin is combined with Pomalidomide.
Ergotamine
The metabolism of Pomalidomide can be decreased when combined with Ergotamine.
Eribulin
The risk or severity of adverse effects can be increased when Eribulin is combined with Pomalidomide.
Erlotinib
The serum concentration of Pomalidomide can be increased when it is combined with Erlotinib.
Eslicarbazepine acetate
The metabolism of Pomalidomide can be increased when combined with Eslicarbazepine acetate.
Estradiol
The metabolism of Pomalidomide can be decreased when combined with Estradiol.
Estradiol acetate
The metabolism of Pomalidomide can be increased when combined with Estradiol acetate.
Estradiol cypionate
The metabolism of Pomalidomide can be increased when combined with Estradiol cypionate.
Estradiol valerate
The metabolism of Pomalidomide can be increased when combined with Estradiol valerate.
Estrone sulfate
The metabolism of Pomalidomide can be decreased when combined with Estrone sulfate.
Etanercept
The metabolism of Pomalidomide can be increased when combined with Etanercept.
Ethambutol
The metabolism of Pomalidomide can be decreased when combined with Ethambutol.
Ethanol
Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Etoposide
The risk or severity of adverse effects can be increased when Etoposide is combined with Pomalidomide.
Etravirine
The metabolism of Pomalidomide can be increased when combined with Etravirine.
Everolimus
The serum concentration of Pomalidomide can be increased when it is combined with Everolimus.
Famotidine
The metabolism of Pomalidomide can be decreased when combined with Famotidine.
Felbamate
The metabolism of Pomalidomide can be increased when combined with Felbamate.
Fexinidazole
The serum concentration of Pomalidomide can be increased when it is combined with Fexinidazole.
Flibanserin
The serum concentration of Pomalidomide can be increased when it is combined with Flibanserin.
Floxuridine
The risk or severity of adverse effects can be increased when Floxuridine is combined with Pomalidomide.
Fluconazole
The serum concentration of Pomalidomide can be increased when it is combined with Fluconazole.
Flucytosine
The risk or severity of adverse effects can be increased when Flucytosine is combined with Pomalidomide.
Fludarabine
The risk or severity of adverse effects can be increased when Fludarabine is combined with Pomalidomide.
Fludrocortisone
The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Pomalidomide.
Flunisolide
The metabolism of Pomalidomide can be increased when combined with Flunisolide.
Fluocinolone acetonide
The metabolism of Pomalidomide can be increased when combined with Fluocinolone acetonide.
Fluocinonide
The metabolism of Pomalidomide can be increased when combined with Fluocinonide.
Fluorometholone
The risk or severity of adverse effects can be increased when Fluorometholone is combined with Pomalidomide.
Fluorouracil
The risk or severity of adverse effects can be increased when Fluorouracil is combined with Pomalidomide.
Fluticasone furoate
The risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Pomalidomide.
Fluticasone propionate
The serum concentration of Pomalidomide can be increased when it is combined with Fluticasone propionate.
Fosamprenavir
The serum concentration of Pomalidomide can be increased when it is combined with Fosamprenavir.
Fosaprepitant
The metabolism of Pomalidomide can be increased when combined with Fosaprepitant.
Fosnetupitant
The metabolism of Pomalidomide can be decreased when combined with Fosnetupitant.
Fosphenytoin
The metabolism of Pomalidomide can be increased when combined with Fosphenytoin.
Fostamatinib
The serum concentration of Pomalidomide can be increased when it is combined with Fostamatinib.
Fusidic acid
The metabolism of Pomalidomide can be decreased when combined with Fusidic acid.
Gatifloxacin
The metabolism of Pomalidomide can be decreased when combined with Gatifloxacin.
Gemcitabine
The risk or severity of adverse effects can be increased when Gemcitabine is combined with Pomalidomide.
Gemfibrozil
The metabolism of Pomalidomide can be decreased when combined with Gemfibrozil.
Gemifloxacin
The metabolism of Pomalidomide can be decreased when combined with Gemifloxacin.
Gemtuzumab ozogamicin
The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pomalidomide.
Genistein
The metabolism of Pomalidomide can be increased when combined with Genistein.
Ginkgo biloba
The metabolism of Pomalidomide can be decreased when combined with Ginkgo biloba.
Glasdegib
The serum concentration of Pomalidomide can be increased when it is combined with Glasdegib.
Glatiramer
The risk or severity of adverse effects can be increased when Glatiramer is combined with Pomalidomide.
Glecaprevir
The serum concentration of Pomalidomide can be increased when it is combined with Glecaprevir.
Glyburide
The metabolism of Pomalidomide can be decreased when combined with Glyburide.
Glycerol phenylbutyrate
The metabolism of Pomalidomide can be increased when combined with Glycerol phenylbutyrate.
Golimumab
The metabolism of Pomalidomide can be increased when combined with Golimumab.
Grapefruit
The serum concentration of Pomalidomide can be increased when it is combined with Grapefruit.
Griseofulvin
The metabolism of Pomalidomide can be increased when combined with Griseofulvin.
Guselkumab
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Guselkumab.
Human adenovirus e serotype 4 strain cl-68578 antigen
The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Pomalidomide.
Hydralazine
The serum concentration of Pomalidomide can be increased when it is combined with Hydralazine.
Hydrocortisone
The metabolism of Pomalidomide can be increased when combined with Hydrocortisone.
Hydrocortisone acetate
The metabolism of Pomalidomide can be increased when combined with Hydrocortisone acetate.
Hydrocortisone butyrate
The metabolism of Pomalidomide can be increased when combined with Hydrocortisone butyrate.
Hydrocortisone succinate
The metabolism of Pomalidomide can be increased when combined with Hydrocortisone succinate.
Hydroxychloroquine
The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Pomalidomide.
Hydroxyurea
The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Pomalidomide.
Ibritumomab tiuxetan
The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pomalidomide.
Ibrutinib
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Ibrutinib.
Idarubicin
The risk or severity of adverse effects can be increased when Idarubicin is combined with Pomalidomide.
Idelalisib
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Idelalisib.
Ifosfamide
The metabolism of Pomalidomide can be increased when combined with Ifosfamide.
Imipramine
The metabolism of Pomalidomide can be decreased when combined with Imipramine.
Indinavir
The metabolism of Pomalidomide can be decreased when combined with Indinavir.
Indomethacin
The risk or severity of adverse effects can be increased when Indomethacin is combined with Pomalidomide.
Infliximab
The metabolism of Pomalidomide can be increased when combined with Infliximab.
Interferon alfa-2b
The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Pomalidomide.
Interferon alfa-n3
The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Pomalidomide.
Interferon beta-1a
The metabolism of Pomalidomide can be decreased when combined with Interferon beta-1a.
Interferon beta-1b
The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Pomalidomide.
Interferon gamma-1b
The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Pomalidomide.
Iptacopan
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Iptacopan.
Irbesartan
The serum concentration of Pomalidomide can be increased when it is combined with Irbesartan.
Irinotecan
The risk or severity of adverse effects can be increased when Irinotecan is combined with Pomalidomide.
Isoniazid
The metabolism of Pomalidomide can be decreased when combined with Isoniazid.
Isradipine
The metabolism of Pomalidomide can be decreased when combined with Isradipine.
Istradefylline
The serum concentration of Pomalidomide can be increased when it is combined with Istradefylline.
Itraconazole
The metabolism of Pomalidomide can be decreased when combined with Itraconazole.
Ixabepilone
The serum concentration of Pomalidomide can be increased when it is combined with Ixabepilone.
Ixekizumab
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Ixekizumab.
Ketoconazole
The metabolism of Pomalidomide can be decreased when combined with Ketoconazole.
Lanreotide
The metabolism of Pomalidomide can be decreased when combined with Lanreotide.
Lapatinib
The serum concentration of Pomalidomide can be increased when it is combined with Lapatinib.
Ledipasvir
The serum concentration of Pomalidomide can be increased when it is combined with Ledipasvir.
Lenalidomide
The risk or severity of adverse effects can be increased when Lenalidomide is combined with Pomalidomide.
Leniolisib
The metabolism of Pomalidomide can be decreased when combined with Leniolisib.
Letermovir
The serum concentration of Pomalidomide can be increased when it is combined with Letermovir.
Levoketoconazole
The metabolism of Pomalidomide can be decreased when combined with Levoketoconazole.
Levothyroxine
The serum concentration of Pomalidomide can be decreased when it is combined with Levothyroxine.
Linagliptin
The serum concentration of Pomalidomide can be increased when it is combined with Linagliptin.
Linezolid
The risk or severity of adverse effects can be increased when Linezolid is combined with Pomalidomide.
Lomitapide
The serum concentration of Pomalidomide can be increased when it is combined with Lomitapide.
Lomustine
The risk or severity of adverse effects can be increased when Lomustine is combined with Pomalidomide.
Lonafarnib
The metabolism of Pomalidomide can be decreased when combined with Lonafarnib.
Lonapegsomatropin
The metabolism of Pomalidomide can be increased when combined with Lonapegsomatropin.
Lorlatinib
The serum concentration of Pomalidomide can be decreased when it is combined with Lorlatinib.
Loxapine
The serum concentration of Pomalidomide can be increased when it is combined with Loxapine.
Maribavir
The serum concentration of Pomalidomide can be increased when it is combined with Maribavir.
Mechlorethamine
The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Pomalidomide.
Medroxyprogesterone acetate
The metabolism of Pomalidomide can be increased when combined with Medroxyprogesterone acetate.
Mefloquine
The serum concentration of Pomalidomide can be increased when it is combined with Mefloquine.
Melphalan
The risk or severity of adverse effects can be increased when Melphalan is combined with Pomalidomide.
Mepolizumab
The risk or severity of adverse effects can be increased when Mepolizumab is combined with Pomalidomide.
Mercaptopurine
The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Pomalidomide.
Methadone
The risk or severity of adverse effects can be increased when Methadone is combined with Pomalidomide.
Methimazole
The metabolism of Pomalidomide can be decreased when combined with Methimazole.
Methotrexate
The risk or severity of adverse effects can be increased when Methotrexate is combined with Pomalidomide.
Methoxsalen
The metabolism of Pomalidomide can be decreased when combined with Methoxsalen.
Methylene blue
The serum concentration of Pomalidomide can be increased when it is combined with Methylene blue.
Methylergometrine
The serum concentration of Pomalidomide can be increased when it is combined with Methylergometrine.
Methylprednisolone
The metabolism of Pomalidomide can be increased when combined with Methylprednisolone.
Metronidazole
The serum concentration of Pomalidomide can be increased when it is combined with Metronidazole.
Metyrapone
The metabolism of Pomalidomide can be increased when combined with Metyrapone.
Mexiletine
The metabolism of Pomalidomide can be decreased when combined with Mexiletine.
Miconazole
The metabolism of Pomalidomide can be decreased when combined with Miconazole.
Midostaurin
The metabolism of Pomalidomide can be decreased when combined with Midostaurin.
Mifepristone
The serum concentration of Pomalidomide can be decreased when it is combined with Mifepristone.
Milnacipran
The metabolism of Pomalidomide can be decreased when combined with Milnacipran.
Mirabegron
The serum concentration of Pomalidomide can be increased when it is combined with Mirabegron.
Mirikizumab
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Mirikizumab.
Mitomycin
The risk or severity of adverse effects can be increased when Mitomycin is combined with Pomalidomide.
Mitotane
The metabolism of Pomalidomide can be increased when combined with Mitotane.
Mitoxantrone
The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Pomalidomide.
Mometasone furoate
The metabolism of Pomalidomide can be increased when combined with Mometasone furoate.
Monomethyl fumarate
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Monomethyl fumarate.
Moxifloxacin
The metabolism of Pomalidomide can be decreased when combined with Moxifloxacin.
Mycophenolate mofetil
The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Pomalidomide.
Mycophenolic acid
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Pomalidomide.
Nafcillin
The metabolism of Pomalidomide can be increased when combined with Nafcillin.
Natalizumab
The risk or severity of immunosuppression can be increased when Pomalidomide is combined with Natalizumab.
Nefazodone
The metabolism of Pomalidomide can be decreased when combined with Nefazodone.
Nelarabine
The risk or severity of adverse effects can be increased when Nelarabine is combined with Pomalidomide.
Nelfinavir
The metabolism of Pomalidomide can be decreased when combined with Nelfinavir.
Neratinib
The serum concentration of Pomalidomide can be increased when it is combined with Neratinib.
Netupitant
The serum concentration of Pomalidomide can be increased when it is combined with Netupitant.
Nevirapine
The metabolism of Pomalidomide can be decreased when combined with Nevirapine.
Niacin
The serum concentration of Pomalidomide can be increased when it is combined with Niacin.
Nicardipine
The metabolism of Pomalidomide can be decreased when combined with Nicardipine.
Nilotinib
The metabolism of Pomalidomide can be decreased when combined with Nilotinib.
Nirogacestat
The serum concentration of Pomalidomide can be increased when it is combined with Nirogacestat.
Norgestimate
The serum concentration of Pomalidomide can be increased when it is combined with Norgestimate.
Obinutuzumab
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Obinutuzumab.
Ocrelizumab
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Ocrelizumab.
Ofatumumab
The risk or severity of adverse effects can be increased when Ofatumumab is combined with Pomalidomide.
Olaparib
The metabolism of Pomalidomide can be decreased when combined with Olaparib.
Oliceridine
The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Pomalidomide is combined with Oliceridine.
Olutasidenib
The metabolism of Pomalidomide can be increased when combined with Olutasidenib.
Oritavancin
The metabolism of Pomalidomide can be increased when combined with Oritavancin.
Oxaliplatin
The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Pomalidomide.
Oxcarbazepine
The metabolism of Pomalidomide can be increased when combined with Oxcarbazepine.
Oxybutynin
The serum concentration of Pomalidomide can be increased when it is combined with Oxybutynin.
Ozanimod
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Ozanimod.
Paclitaxel
The metabolism of Pomalidomide can be increased when combined with Paclitaxel.
Palbociclib
The serum concentration of Pomalidomide can be increased when it is combined with Palbociclib.
Paliperidone
The serum concentration of Pomalidomide can be increased when it is combined with Paliperidone.
Palovarotene
The metabolism of Pomalidomide can be increased when combined with Palovarotene.
Panobinostat
The risk or severity of adverse effects can be increased when Panobinostat is combined with Pomalidomide.
Pasireotide
The metabolism of Pomalidomide can be decreased when combined with Pasireotide.
Pazopanib
The metabolism of Pomalidomide can be decreased when combined with Pazopanib.
Pegaspargase
The risk or severity of adverse effects can be increased when Pegaspargase is combined with Pomalidomide.
Pegcetacoplan
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Pegcetacoplan.
Peginterferon alfa-2a
The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Pomalidomide.
Peginterferon beta-1a
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Peginterferon beta-1a.
Pemetrexed
The risk or severity of adverse effects can be increased when Pemetrexed is combined with Pomalidomide.
Penicillamine
The risk or severity of adverse effects can be increased when Penicillamine is combined with Pomalidomide.
Pentobarbital
The metabolism of Pomalidomide can be increased when combined with Pentobarbital.
Pentostatin
The risk or severity of adverse effects can be increased when Pentostatin is combined with Pomalidomide.
Phenobarbital
The metabolism of Pomalidomide can be increased when combined with Phenobarbital.
Phenylalanine
The risk or severity of adverse effects can be increased when Phenylalanine is combined with Pomalidomide.
Phenylephrine
The metabolism of Pomalidomide can be increased when combined with Phenylephrine.
Phenytoin
The metabolism of Pomalidomide can be increased when combined with Phenytoin.
Pibrentasvir
The serum concentration of Pomalidomide can be increased when it is combined with Pibrentasvir.
Pimecrolimus
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pomalidomide.
Pimozide
The metabolism of Pomalidomide can be decreased when combined with Pimozide.
Piperine
The serum concentration of Pomalidomide can be increased when it is combined with Piperine.
Pirfenidone
The risk or severity of adverse effects can be increased when Pirfenidone is combined with Pomalidomide.
Pirtobrutinib
The serum concentration of Pomalidomide can be increased when it is combined with Pirtobrutinib.
Ponatinib
The serum concentration of Pomalidomide can be increased when it is combined with Ponatinib.
Ponesimod
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Ponesimod.
Posaconazole
The metabolism of Pomalidomide can be decreased when combined with Posaconazole.
Pozelimab
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Pozelimab.
Pralatrexate
The risk or severity of adverse effects can be increased when Pralatrexate is combined with Pomalidomide.
Pralsetinib
The serum concentration of Pomalidomide can be increased when it is combined with Pralsetinib.
Prednisolone
The metabolism of Pomalidomide can be increased when combined with Prednisolone.
Prednisolone acetate
The metabolism of Pomalidomide can be increased when combined with Prednisolone acetate.
Prednisolone phosphate
The serum concentration of Pomalidomide can be decreased when it is combined with Prednisolone phosphate.
Prednisone
The risk or severity of adverse effects can be increased when Prednisone is combined with Pomalidomide.
Primaquine
The metabolism of Pomalidomide can be decreased when combined with Primaquine.
Primidone
The metabolism of Pomalidomide can be increased when combined with Primidone.
Probenecid
The metabolism of Pomalidomide can be increased when combined with Probenecid.
Procarbazine
The risk or severity of adverse effects can be increased when Procarbazine is combined with Pomalidomide.
Propafenone
The serum concentration of Pomalidomide can be increased when it is combined with Propafenone.
Propofol
The metabolism of Pomalidomide can be decreased when combined with Propofol.
Propylthiouracil
The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Pomalidomide.
Quinine
The serum concentration of Pomalidomide can be increased when it is combined with Quinine.
Quinupristin
The metabolism of Pomalidomide can be decreased when combined with Quinupristin.
Quizartinib
The serum concentration of Pomalidomide can be increased when it is combined with Quizartinib.
Raloxifene
The serum concentration of Pomalidomide can be increased when it is combined with Raloxifene.
Ravulizumab
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Ravulizumab.
Regorafenib
The serum concentration of Pomalidomide can be increased when it is combined with Regorafenib.
Remdesivir
The metabolism of Pomalidomide can be decreased when combined with Remdesivir.
Reserpine
The serum concentration of Pomalidomide can be increased when it is combined with Reserpine.
Rifabutin
The metabolism of Pomalidomide can be increased when combined with Rifabutin.
Rifampin
The serum concentration of Pomalidomide can be decreased when it is combined with Rifampicin.
Rifapentine
The metabolism of Pomalidomide can be increased when combined with Rifapentine.
Rilonacept
The metabolism of Pomalidomide can be increased when combined with Rilonacept.
Rilpivirine
The metabolism of Pomalidomide can be decreased when combined with Rilpivirine.
Ripretinib
The serum concentration of Pomalidomide can be increased when it is combined with Ripretinib.
Risankizumab
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Risankizumab.
Rituximab
The risk or severity of adverse effects can be increased when Rituximab is combined with Pomalidomide.
Rolapitant
The serum concentration of Pomalidomide can be increased when it is combined with Rolapitant.
Rozanolixizumab
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Rozanolixizumab.
Rubella virus vaccine
The risk or severity of infection can be increased when Rubella virus vaccine is combined with Pomalidomide.
Ruxolitinib
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Pomalidomide.
Sapropterin
The serum concentration of Pomalidomide can be increased when it is combined with Sapropterin.
Saquinavir
The metabolism of Pomalidomide can be decreased when combined with Saquinavir.
Sarecycline
The serum concentration of Pomalidomide can be increased when it is combined with Sarecycline.
Sarilumab
The metabolism of Pomalidomide can be increased when combined with Sarilumab.
Sebetralstat
The serum concentration of Pomalidomide can be increased when it is combined with Sebetralstat.
Secobarbital
The metabolism of Pomalidomide can be increased when combined with Secobarbital.
Secukinumab
The metabolism of Pomalidomide can be increased when combined with Secukinumab.
Sildenafil
The serum concentration of Pomalidomide can be increased when it is combined with Sildenafil.
Siltuximab
The metabolism of Pomalidomide can be increased when combined with Siltuximab.
Simvastatin
The serum concentration of Pomalidomide can be increased when it is combined with Simvastatin.
Siponimod
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Siponimod.
Sirolimus
The risk or severity of adverse effects can be increased when Sirolimus is combined with Pomalidomide.
Smallpox (Vaccinia) Vaccine, Live
The risk or severity of infection can be increased when Smallpox (Vaccinia) Vaccine, Live is combined with Pomalidomide.
Sodium oxybate
Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Somapacitan
The metabolism of Pomalidomide can be increased when combined with Somapacitan.
Somatotropin
The metabolism of Pomalidomide can be increased when combined with Somatotropin.
Sorafenib
The serum concentration of Pomalidomide can be increased when it is combined with Sorafenib.
Sotagliflozin
The serum concentration of Pomalidomide can be increased when it is combined with Sotagliflozin.
Sotorasib
The serum concentration of Pomalidomide can be decreased when it is combined with Sotorasib.
Sparsentan
The serum concentration of Pomalidomide can be increased when it is combined with Sparsentan.
Spesolimab
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Spesolimab.
Stiripentol
The metabolism of Pomalidomide can be decreased when combined with Stiripentol.
Streptozocin
The risk or severity of adverse effects can be increased when Streptozocin is combined with Pomalidomide.
Sulfasalazine
The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Pomalidomide.
Sunitinib
The risk or severity of adverse effects can be increased when Sunitinib is combined with Pomalidomide.
Sutimlimab
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Sutimlimab.
Taletrectinib
The serum concentration of Pomalidomide can be increased when it is combined with Taletrectinib.
Tamoxifen
The serum concentration of Pomalidomide can be increased when it is combined with Tamoxifen.
Tecovirimat
The metabolism of Pomalidomide can be increased when combined with Tecovirimat.
Tegaserod
The metabolism of Pomalidomide can be decreased when combined with Tegaserod.
Telithromycin
The metabolism of Pomalidomide can be decreased when combined with Telithromycin.
Temozolomide
The risk or severity of adverse effects can be increased when Temozolomide is combined with Pomalidomide.
Temsirolimus
The serum concentration of Pomalidomide can be increased when it is combined with Temsirolimus.
Teniposide
The serum concentration of Pomalidomide can be increased when it is combined with Teniposide.
Tepotinib
The serum concentration of Pomalidomide can be increased when it is combined with Tepotinib.
Teprotumumab
The risk or severity of adverse effects can be increased when Teprotumumab is combined with Pomalidomide.
Terbinafine
The metabolism of Pomalidomide can be increased when combined with Terbinafine.
Testosterone
The metabolism of Pomalidomide can be increased when combined with Testosterone.
Tetracycline
The serum concentration of Pomalidomide can be increased when it is combined with Tetracycline.
Thalidomide
Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Theophylline
The metabolism of Pomalidomide can be decreased when combined with Theophylline.
Thiotepa
The risk or severity of adverse effects can be increased when Thiotepa is combined with Pomalidomide.
Ticagrelor
The serum concentration of Pomalidomide can be increased when it is combined with Ticagrelor.
Ticlopidine
The metabolism of Pomalidomide can be decreased when combined with Ticlopidine.
Tioguanine
The risk or severity of adverse effects can be increased when Tioguanine is combined with Pomalidomide.
Tipranavir
The metabolism of Pomalidomide can be decreased when combined with Tipranavir.
Tixocortol
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Tixocortol.
Tizanidine
The metabolism of Pomalidomide can be decreased when combined with Tizanidine.
Tocilizumab
The metabolism of Pomalidomide can be increased when combined with Tocilizumab.
Topiramate
The metabolism of Pomalidomide can be increased when combined with Topiramate.
Topotecan
The risk or severity of adverse effects can be increased when Topotecan is combined with Pomalidomide.
Toremifene
The serum concentration of Pomalidomide can be increased when it is combined with Toremifene.
Trabectedin
The risk or severity of adverse effects can be increased when Trabectedin is combined with Pomalidomide.
Trastuzumab emtansine
The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Pomalidomide.
Trazodone
The serum concentration of Pomalidomide can be decreased when it is combined with Trazodone.
Treosulfan
The serum concentration of Pomalidomide can be increased when it is combined with Treosulfan.
Triamcinolone
The metabolism of Pomalidomide can be increased when combined with Triamcinolone.
Triclabendazole
The serum concentration of Pomalidomide can be increased when it is combined with Triclabendazole.
Trifluridine
The risk or severity of adverse effects can be increased when Trifluridine is combined with Pomalidomide.
Trilaciclib
The metabolism of Pomalidomide can be increased when combined with Trilaciclib.
Trovafloxacin
The metabolism of Pomalidomide can be decreased when combined with Trovafloxacin.
Typhoid Vaccine Live
The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Pomalidomide.
Upadacitinib
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Upadacitinib.
Valproic acid
The serum concentration of Pomalidomide can be increased when it is combined with Valproic acid.
Vandetanib
The serum concentration of Pomalidomide can be increased when it is combined with Vandetanib.
Vardenafil
The serum concentration of Pomalidomide can be increased when it is combined with Vardenafil.
Varicella zoster vaccine (live/attenuated)
The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Pomalidomide.
Vedolizumab
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Vedolizumab.
Velpatasvir
The serum concentration of Pomalidomide can be increased when it is combined with Velpatasvir.
Venetoclax
The serum concentration of Pomalidomide can be increased when it is combined with Venetoclax.
Verapamil
The serum concentration of Pomalidomide can be increased when it is combined with Verapamil.
Vilanterol
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Vilanterol.
Viloxazine
The metabolism of Pomalidomide can be decreased when combined with Viloxazine.
Vinblastine
The metabolism of Pomalidomide can be increased when combined with Vinblastine.
Vincristine
The risk or severity of adverse effects can be increased when Vincristine is combined with Pomalidomide.
Vinorelbine
The risk or severity of adverse effects can be increased when Vinorelbine is combined with Pomalidomide.
Vitamin E
The metabolism of Pomalidomide can be increased when combined with Vitamin E.
Vorapaxar
The serum concentration of Pomalidomide can be increased when it is combined with Vorapaxar.
Vorasidenib
The metabolism of Pomalidomide can be increased when combined with Vorasidenib.
Voriconazole
The metabolism of Pomalidomide can be decreased when combined with Voriconazole.
Vorinostat
The risk or severity of adverse effects can be increased when Vorinostat is combined with Pomalidomide.
Voxelotor
The serum concentration of Pomalidomide can be increased when it is combined with Voxelotor.
Voxilaprevir
The serum concentration of Pomalidomide can be increased when it is combined with Voxilaprevir.
Warfarin
The metabolism of Pomalidomide can be increased when combined with Warfarin.
Yellow fever vaccine
The risk or severity of infection can be increased when Yellow fever vaccine is combined with Pomalidomide.
Zafirlukast
The serum concentration of Pomalidomide can be increased when it is combined with Zafirlukast.
Zidovudine
The risk or severity of adverse effects can be increased when Zidovudine is combined with Pomalidomide.
Zileuton
The metabolism of Pomalidomide can be decreased when combined with Zileuton.
Zilucoplan
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Zilucoplan.
Zonisamide
The serum concentration of Pomalidomide can be increased when it is combined with Zonisamide.
Abemaciclib
The serum concentration of Abemaciclib can be increased when it is combined with Pomalidomide.
Acyclovir
The metabolism of Pomalidomide can be decreased when combined with Acyclovir.
Alendronic acid
The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Pomalidomide is combined with Alendronic acid.
Alfentanil
The risk or severity of CNS depression can be increased when Alfentanil is combined with Pomalidomide.
Allopurinol
The risk or severity of adverse effects can be increased when Allopurinol is combined with Pomalidomide.
Almotriptan
The risk or severity of CNS depression can be increased when Almotriptan is combined with Pomalidomide.
Alprazolam
The risk or severity of CNS depression can be increased when Alprazolam is combined with Pomalidomide.
Ambrisentan
The serum concentration of Pomalidomide can be increased when it is combined with Ambrisentan.
Amikacin
Pomalidomide may decrease the excretion rate of Amikacin which could result in a higher serum level.
Amiodarone
The serum concentration of Pomalidomide can be increased when it is combined with Amiodarone.
Amisulpride
The risk or severity of CNS depression can be increased when Amisulpride is combined with Pomalidomide.
Amitriptyline
The risk or severity of CNS depression can be increased when Amitriptyline is combined with Pomalidomide.
Amoxapine
The risk or severity of CNS depression can be increased when Amoxapine is combined with Pomalidomide.
Anthrax immune globulin human
The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Pomalidomide.
Antipyrine
The metabolism of Pomalidomide can be decreased when combined with Antipyrine.
Apalutamide
The serum concentration of Pomalidomide can be decreased when it is combined with Apalutamide.
Apixaban
The serum concentration of Pomalidomide can be increased when it is combined with Apixaban.
Apomorphine
The risk or severity of CNS depression can be increased when Apomorphine is combined with Pomalidomide.
Aripiprazole
The risk or severity of CNS depression can be increased when Aripiprazole is combined with Pomalidomide.
Aripiprazole lauroxil
The risk or severity of CNS depression can be increased when Pomalidomide is combined with Aripiprazole lauroxil.
Armodafinil
The metabolism of Pomalidomide can be increased when combined with Armodafinil.
Articaine
The risk or severity of methemoglobinemia can be increased when Pomalidomide is combined with Articaine.
Asciminib
The serum concentration of Pomalidomide can be increased when it is combined with Asciminib.
Asenapine
The risk or severity of CNS depression can be increased when Asenapine is combined with Pomalidomide.
AstraZeneca COVID-19 Vaccine
The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Pomalidomide.
Atracurium besylate
The risk or severity of CNS depression can be increased when Atracurium besylate is combined with Pomalidomide.
Avanafil
The serum concentration of Avanafil can be increased when it is combined with Pomalidomide.
Azithromycin
The metabolism of Pomalidomide can be decreased when combined with Azithromycin.
Belzutifan
The serum concentration of Pomalidomide can be decreased when it is combined with Belzutifan.
Benzocaine
The risk or severity of methemoglobinemia can be increased when Pomalidomide is combined with Benzocaine.
Benzphetamine
The risk or severity of CNS depression can be increased when Benzphetamine is combined with Pomalidomide.
Benzyl alcohol
The risk or severity of methemoglobinemia can be increased when Pomalidomide is combined with Benzyl alcohol.
Berotralstat
The serum concentration of Pomalidomide can be increased when it is combined with Berotralstat.
Betaxolol
The metabolism of Pomalidomide can be decreased when combined with Betaxolol.
Betrixaban
The serum concentration of Pomalidomide can be increased when it is combined with Betrixaban.
Bisoprolol
The serum concentration of Pomalidomide can be increased when it is combined with Bisoprolol.
Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated)
The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Pomalidomide.
Botulinum toxin type B
The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Pomalidomide.
Brexanolone
The risk or severity of CNS depression can be increased when Pomalidomide is combined with Brexanolone.
Brexpiprazole
The risk or severity of CNS depression can be increased when Pomalidomide is combined with Brexpiprazole.
Brimonidine
Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.
Brivaracetam
The risk or severity of CNS depression can be increased when Brivaracetam is combined with Pomalidomide.
Bromocriptine
The risk or severity of CNS depression can be increased when Bromocriptine is combined with Pomalidomide.
Bromotheophylline
The metabolism of Bromotheophylline can be decreased when combined with Pomalidomide.
Brompheniramine
The risk or severity of CNS depression can be increased when Brompheniramine is combined with Pomalidomide.
Bupivacaine
The risk or severity of methemoglobinemia can be increased when Pomalidomide is combined with Bupivacaine.
Buprenorphine
Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Bupropion
The risk or severity of CNS depression can be increased when Bupropion is combined with Pomalidomide.
Buspirone
The risk or severity of CNS depression can be increased when Buspirone is combined with Pomalidomide.
Butamben
The risk or severity of methemoglobinemia can be increased when Pomalidomide is combined with Butamben.
Butorphanol
The risk or severity of CNS depression can be increased when Butorphanol is combined with Pomalidomide.
Cabergoline
The risk or severity of CNS depression can be increased when Cabergoline is combined with Pomalidomide.
Cannabidiol
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Pomalidomide.
Capmatinib
The serum concentration of Pomalidomide can be increased when it is combined with Capmatinib.
Capreomycin
Pomalidomide may decrease the excretion rate of Capreomycin which could result in a higher serum level.
Capsaicin
The risk or severity of methemoglobinemia can be increased when Pomalidomide is combined with Capsaicin.
Carbinoxamine
The risk or severity of CNS depression can be increased when Carbinoxamine is combined with Pomalidomide.
Cariprazine
The risk or severity of CNS depression can be increased when Cariprazine is combined with Pomalidomide.
Carisoprodol
The risk or severity of adverse effects can be increased when Carisoprodol is combined with Pomalidomide.
Cenobamate
The serum concentration of Pomalidomide can be decreased when it is combined with Cenobamate.
Cephalexin
The metabolism of Pomalidomide can be decreased when combined with Cephalexin.
Cetirizine
The risk or severity of CNS depression can be increased when Cetirizine is combined with Pomalidomide.
Chlordiazepoxide
The risk or severity of CNS depression can be increased when Chlordiazepoxide is combined with Pomalidomide.
Chloroprocaine
The risk or severity of methemoglobinemia can be increased when Pomalidomide is combined with Chloroprocaine.
Chlorpheniramine
The risk or severity of CNS depression can be increased when Chlorpheniramine is combined with Pomalidomide.
Chlorzoxazone
The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with Pomalidomide.
Cilostazol
The metabolism of Pomalidomide can be decreased when combined with Cilostazol.
Cinacalcet
The metabolism of Pomalidomide can be decreased when combined with Cinacalcet.
Cinchocaine
The risk or severity of methemoglobinemia can be increased when Pomalidomide is combined with Cinchocaine.
Ciprofloxacin
The serum concentration of Pomalidomide can be increased when it is combined with Ciprofloxacin.
Cisatracurium
The risk or severity of CNS depression can be increased when Cisatracurium is combined with Pomalidomide.
Clemastine
The risk or severity of CNS depression can be increased when Clemastine is combined with Pomalidomide.
Clidinium
The risk or severity of CNS depression can be increased when Clidinium is combined with Pomalidomide.
Clobazam
The risk or severity of sedation, somnolence, and CNS depression can be increased when Clobazam is combined with Pomalidomide.
Clomifene
The serum concentration of Pomalidomide can be increased when it is combined with Clomifene.
Clonazepam
The risk or severity of CNS depression can be increased when Clonazepam is combined with Pomalidomide.
Clopidogrel
The metabolism of Pomalidomide can be decreased when combined with Clopidogrel.
Clorazepic acid
The risk or severity of CNS depression can be increased when Clorazepic acid is combined with Pomalidomide.
Clostridium tetani toxoid antigen (formaldehyde inactivated)
The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Pomalidomide.
Clozapine
The risk or severity of neutropenia can be increased when Pomalidomide is combined with Clozapine.
Cobimetinib
The metabolism of Pomalidomide can be decreased when combined with Cobimetinib.
Cocaine
The risk or severity of methemoglobinemia can be increased when Pomalidomide is combined with Cocaine.
Codeine
The risk or severity of CNS depression can be increased when Codeine is combined with Pomalidomide.
Colchicine
The serum concentration of Pomalidomide can be increased when it is combined with Colchicine.
Colistin
Pomalidomide may decrease the excretion rate of Colistin which could result in a higher serum level.
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Pomalidomide.
Crizotinib
The metabolism of Pomalidomide can be decreased when combined with Crizotinib.
Cyanocobalamin
The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Pomalidomide.
Cyclobenzaprine
The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Pomalidomide.
Cyproheptadine
The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Pomalidomide.
Dabigatran etexilate
The serum concentration of Pomalidomide can be increased when it is combined with Dabigatran etexilate.
Dabrafenib
The serum concentration of Pomalidomide can be decreased when it is combined with Dabrafenib.
Danicopan
The serum concentration of Pomalidomide can be increased when it is combined with Danicopan.
Dantrolene
The risk or severity of CNS depression can be increased when Dantrolene is combined with Pomalidomide.
Daptomycin
The serum concentration of Pomalidomide can be increased when it is combined with Daptomycin.
Darbepoetin alfa
The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Pomalidomide.
Darolutamide
The serum concentration of Pomalidomide can be increased when it is combined with Darolutamide.
Dasabuvir
The serum concentration of Pomalidomide can be increased when it is combined with Dasabuvir.
Denosumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Pomalidomide.
Desflurane
The risk or severity of CNS depression can be increased when Desflurane is combined with Pomalidomide.
Desloratadine
The risk or severity of CNS depression can be increased when Desloratadine is combined with Pomalidomide.
Deutivacaftor
The serum concentration of Pomalidomide can be increased when it is combined with Deutivacaftor.
Dexbrompheniramine
The risk or severity of CNS depression can be increased when Dexbrompheniramine is combined with Pomalidomide.
Dexmethylphenidate
The risk or severity of CNS depression can be increased when Dexmethylphenidate is combined with Pomalidomide.
Dextromethorphan
The risk or severity of CNS depression can be increased when Dextromethorphan is combined with Pomalidomide.
Diazepam
The risk or severity of CNS depression can be increased when Diazepam is combined with Pomalidomide.
Diclofenac
The metabolism of Pomalidomide can be decreased when combined with Diclofenac.
Diethylpropion
The risk or severity of CNS depression can be increased when Diethylpropion is combined with Pomalidomide.
Difenoxin
The risk or severity of CNS depression can be increased when Difenoxin is combined with Pomalidomide.
Digoxin
Pomalidomide may decrease the excretion rate of Digoxin which could result in a higher serum level.
Dihydrocodeine
The risk or severity of CNS depression can be increased when Dihydrocodeine is combined with Pomalidomide.
Dihydroergocornine
The metabolism of Pomalidomide can be decreased when combined with Dihydroergocornine.
Dihydroergocristine
The metabolism of Pomalidomide can be decreased when combined with Dihydroergocristine.
Dimenhydrinate
The risk or severity of CNS depression can be increased when Dimenhydrinate is combined with Pomalidomide.
Diphenhydramine
The risk or severity of methemoglobinemia can be increased when Pomalidomide is combined with Diphenhydramine.
Diphenoxylate
The risk or severity of CNS depression can be increased when Diphenoxylate is combined with Pomalidomide.
Disopyramide
The metabolism of Pomalidomide can be decreased when combined with Disopyramide.
Dolasetron
The risk or severity of CNS depression can be increased when Dolasetron is combined with Pomalidomide.
Dolutegravir
The serum concentration of Pomalidomide can be increased when it is combined with Dolutegravir.
Donepezil
The risk or severity of CNS depression can be increased when Donepezil is combined with Pomalidomide.
Doxazosin
The metabolism of Pomalidomide can be decreased when combined with Doxazosin.
Doxepin
The risk or severity of CNS depression can be increased when Doxepin is combined with Pomalidomide.
Doxylamine
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.
Dronabinol
Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.
Dronedarone
The serum concentration of Pomalidomide can be increased when it is combined with Dronedarone.
Droperidol
Droperidol may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.
Drospirenone
The metabolism of Pomalidomide can be decreased when combined with Drospirenone.
Duloxetine
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Duloxetine.
Duvelisib
The metabolism of Pomalidomide can be decreased when combined with Duvelisib.
Dyclonine
The risk or severity of methemoglobinemia can be increased when Pomalidomide is combined with Dyclonine.
Ebola Zaire vaccine (live, attenuated)
The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Pomalidomide.
Edoxaban
The serum concentration of Pomalidomide can be increased when it is combined with Edoxaban.
Elacestrant
The serum concentration of Pomalidomide can be increased when it is combined with Elacestrant.
Elasomeran
The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Pomalidomide.
Elbasvir
The serum concentration of Pomalidomide can be increased when it is combined with Elbasvir.
Eletriptan
The risk or severity of CNS depression can be increased when Eletriptan is combined with Pomalidomide.
Elexacaftor
The metabolism of Pomalidomide can be decreased when combined with Elexacaftor.
Eliglustat
The serum concentration of Pomalidomide can be increased when it is combined with Eliglustat.
Eltrombopag
The metabolism of Pomalidomide can be decreased when combined with Eltrombopag.
Enfortumab vedotin
The serum concentration of Pomalidomide can be increased when it is combined with Enfortumab vedotin.
Entacapone
The risk or severity of CNS depression can be increased when Entacapone is combined with Pomalidomide.
Entecavir
The metabolism of Pomalidomide can be decreased when combined with Entecavir.
Enzalutamide
The serum concentration of Pomalidomide can be decreased when it is combined with Enzalutamide.
Epcoritamab
The serum concentration of Pomalidomide can be increased when it is combined with Epcoritamab.
Epinastine
The risk or severity of CNS depression can be increased when Epinastine is combined with Pomalidomide.
Erdafitinib
The serum concentration of Pomalidomide can be increased when it is combined with Erdafitinib.
Erythromycin
The serum concentration of Pomalidomide can be increased when it is combined with Erythromycin.
Erythropoietin
The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Pomalidomide.
Escitalopram
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Escitalopram.
Esketamine
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Esketamine.
Estazolam
The risk or severity of CNS depression can be increased when Estazolam is combined with Pomalidomide.
Estetrol
The metabolism of Pomalidomide can be decreased when combined with Estetrol.
Eszopiclone
The risk or severity of CNS depression can be increased when Pomalidomide is combined with Eszopiclone.
Ethinylestradiol
The metabolism of Pomalidomide can be decreased when combined with Ethinylestradiol.
Ethosuximide
The risk or severity of CNS depression can be increased when Ethosuximide is combined with Pomalidomide.
Ethotoin
The risk or severity of CNS depression can be increased when Ethotoin is combined with Pomalidomide.
Etomidate
The risk or severity of CNS depression can be increased when Etomidate is combined with Pomalidomide.
Etrasimod
The risk or severity of immunosuppression can be increased when Pomalidomide is combined with Etrasimod.
Fedratinib
The serum concentration of Pomalidomide can be increased when it is combined with Fedratinib.
Fenfluramine
The risk or severity of CNS depression can be increased when Fenfluramine is combined with Pomalidomide.
Fenofibrate
The metabolism of Pomalidomide can be decreased when combined with Fenofibrate.
Fentanyl
The risk or severity of CNS depression can be increased when Fentanyl is combined with Pomalidomide.
Fexofenadine
The serum concentration of Pomalidomide can be increased when it is combined with Fexofenadine.
Fezolinetant
The metabolism of Fezolinetant can be decreased when combined with Pomalidomide.
Fingolimod
Pomalidomide may increase the immunosuppressive activities of Fingolimod.
Flecainide
The metabolism of Pomalidomide can be decreased when combined with Flecainide.
Fluoxetine
Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.
Fluphenazine
The risk or severity of CNS depression can be increased when Fluphenazine is combined with Pomalidomide.
Flurazepam
The risk or severity of CNS depression can be increased when Flurazepam is combined with Pomalidomide.
Flutamide
The metabolism of Pomalidomide can be decreased when combined with Flutamide.
Fluvoxamine
The serum concentration of Pomalidomide can be increased when it is combined with Fluvoxamine.
Fostemsavir
The serum concentration of Pomalidomide can be increased when it is combined with Fostemsavir.
Frovatriptan
The risk or severity of CNS depression can be increased when Frovatriptan is combined with Pomalidomide.
Futibatinib
The serum concentration of Pomalidomide can be increased when it is combined with Futibatinib.
Gabapentin
The risk or severity of CNS depression can be increased when Gabapentin is combined with Pomalidomide.
Gabapentin enacarbil
The risk or severity of CNS depression can be increased when Gabapentin enacarbil is combined with Pomalidomide.
gamma-Hydroxybutyric acid
The risk or severity of CNS depression can be increased when gamma-Hydroxybutyric acid is combined with Pomalidomide.
Ganaxolone
The risk or severity of sedation, somnolence, and CNS depression can be increased when Pomalidomide is combined with Ganaxolone.
Gentamicin
Pomalidomide may decrease the excretion rate of Gentamicin which could result in a higher serum level.
Gepirone
The risk or severity of CNS depression can be increased when Pomalidomide is combined with Gepirone.
Gilteritinib
The metabolism of Pomalidomide can be decreased when combined with Gilteritinib.
Givinostat
The serum concentration of Pomalidomide can be increased when it is combined with Givinostat.
Givosiran
The serum concentration of Pomalidomide can be increased when it is combined with Givosiran.
Glofitamab
The serum concentration of Pomalidomide can be increased when it is combined with Glofitamab.
Granisetron
The risk or severity of CNS depression can be increased when Granisetron is combined with Pomalidomide.
Grazoprevir
The serum concentration of Pomalidomide can be increased when it is combined with Grazoprevir.
Guanfacine
The risk or severity of CNS depression can be increased when Guanfacine is combined with Pomalidomide.
Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen
The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Pomalidomide.
Haloperidol
The risk or severity of CNS depression can be increased when Haloperidol is combined with Pomalidomide.
Hepatitis A Vaccine
The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Pomalidomide.
Hepatitis B Vaccine (Recombinant)
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Pomalidomide.
Hydrocodone
Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydromorphone
The risk or severity of CNS depression can be increased when Hydromorphone is combined with Pomalidomide.
Hydroxyzine
Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.
Ibandronate
The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Pomalidomide is combined with Ibandronate.
Iloperidone
The risk or severity of CNS depression can be increased when Iloperidone is combined with Pomalidomide.
Imatinib
The serum concentration of Pomalidomide can be increased when it is combined with Imatinib.
Infigratinib
The metabolism of Pomalidomide can be decreased when combined with Infigratinib.
Isavuconazonium
The serum concentration of Pomalidomide can be increased when it is combined with Isavuconazonium.
Isocarboxazid
The risk or severity of CNS depression can be increased when Isocarboxazid is combined with Pomalidomide.
Isoflurane
The risk or severity of CNS depression can be increased when Isoflurane is combined with Pomalidomide.
Ivacaftor
The serum concentration of Pomalidomide can be increased when it is combined with Ivacaftor.
Ivosidenib
The metabolism of Pomalidomide can be increased when combined with Ivosidenib.
Janssen COVID-19 Vaccine
The therapeutic efficacy of Janssen COVID-19 Vaccine can be decreased when used in combination with Pomalidomide.
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)
The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Pomalidomide.
Ketamine
The risk or severity of CNS depression can be increased when Ketamine is combined with Pomalidomide.
Lacosamide
The metabolism of Pomalidomide can be decreased when combined with Lacosamide.
Lamotrigine
The risk or severity of CNS depression can be increased when Lamotrigine is combined with Pomalidomide.
Lasmiditan
The serum concentration of Pomalidomide can be increased when it is combined with Lasmiditan.
Lefamulin
The serum concentration of Pomalidomide can be increased when it is combined with Lefamulin.
Leflunomide
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Leflunomide.
Lemborexant
The risk or severity of CNS depression can be increased when Pomalidomide is combined with Lemborexant.
Lenvatinib
The serum concentration of Pomalidomide can be increased when it is combined with Lenvatinib.
Levetiracetam
The risk or severity of CNS depression can be increased when Levetiracetam is combined with Pomalidomide.
Levocetirizine
The risk or severity of CNS depression can be increased when Levocetirizine is combined with Pomalidomide.
Levodopa
The risk or severity of CNS depression can be increased when Levodopa is combined with Pomalidomide.
Levorphanol
The risk or severity of CNS depression can be increased when Levorphanol is combined with Pomalidomide.
Lidocaine
The risk or severity of methemoglobinemia can be increased when Pomalidomide is combined with Lidocaine.
Lithium carbonate
Pomalidomide may decrease the excretion rate of Lithium carbonate which could result in a higher serum level.
Lofexidine
The therapeutic efficacy of Pomalidomide can be increased when used in combination with Lofexidine.
Lomefloxacin
The metabolism of Pomalidomide can be decreased when combined with Lomefloxacin.
Loncastuximab tesirine
The serum concentration of Pomalidomide can be increased when it is combined with Loncastuximab tesirine.
Loperamide
The serum concentration of Pomalidomide can be increased when it is combined with Loperamide.
Lopinavir
The serum concentration of Pomalidomide can be increased when it is combined with Lopinavir.
Lorazepam
The risk or severity of CNS depression can be increased when Lorazepam is combined with Pomalidomide.
Lumacaftor
The serum concentration of Pomalidomide can be decreased when it is combined with Lumacaftor.
Lumateperone
The risk or severity of CNS depression can be increased when Lumateperone is combined with Pomalidomide.
Lurasidone
The risk or severity of CNS depression can be increased when Lurasidone is combined with Pomalidomide.
Lusutrombopag
The serum concentration of Pomalidomide can be increased when it is combined with Lusutrombopag.
Magnesium
The serum concentration of Magnesium can be decreased when it is combined with Pomalidomide.
Magnesium sulfate
The therapeutic efficacy of Pomalidomide can be increased when used in combination with Magnesium sulfate.
Mannitol
The serum concentration of Pomalidomide can be increased when it is combined with Mannitol.
Maprotiline
The risk or severity of CNS depression can be increased when Maprotiline is combined with Pomalidomide.
Mavacamten
The serum concentration of Pomalidomide can be decreased when it is combined with Mavacamten.
Measles virus vaccine live attenuated
The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Pomalidomide.
Meclizine
The risk or severity of CNS depression can be increased when Meclizine is combined with Pomalidomide.
Mefenamic acid
The metabolism of Pomalidomide can be decreased when combined with Mefenamic acid.
Melatonin
The risk or severity of CNS depression can be increased when Melatonin is combined with Pomalidomide.
Meloxicam
The risk or severity of methemoglobinemia can be increased when Pomalidomide is combined with Meloxicam.
Meperidine
The metabolism of Pomalidomide can be decreased when combined with Meperidine.
Mepivacaine
The risk or severity of methemoglobinemia can be increased when Pomalidomide is combined with Mepivacaine.
Meprobamate
The risk or severity of CNS depression can be increased when Meprobamate is combined with Pomalidomide.
Mepyramine
The risk or severity of CNS depression can be increased when Mepyramine is combined with Pomalidomide.
Metaxalone
The risk or severity of CNS depression can be increased when Metaxalone is combined with Pomalidomide.
Methocarbamol
The risk or severity of CNS depression can be increased when Methocarbamol is combined with Pomalidomide.
Methohexital
The risk or severity of CNS depression can be increased when Methohexital is combined with Pomalidomide.
Methoxy polyethylene glycol-epoetin beta
The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Pomalidomide.
Methsuximide
The risk or severity of CNS depression can be increased when Methsuximide is combined with Pomalidomide.
Metoclopramide
The risk or severity of sedation can be increased when Metoclopramide is combined with Pomalidomide.
Metyrosine
Pomalidomide may increase the sedative activities of Metyrosine.
Midazolam
The risk or severity of sedation and CNS depression can be increased when Midazolam is combined with Pomalidomide.
Mirtazapine
Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Modafinil
The metabolism of Pomalidomide can be increased when combined with Modafinil.
Modified vaccinia ankara
The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Pomalidomide.
Molindone
The risk or severity of CNS depression can be increased when Molindone is combined with Pomalidomide.
Morphine
The risk or severity of CNS depression can be increased when Morphine is combined with Pomalidomide.
mRNA-1345
The therapeutic efficacy of mRNA-1345 can be decreased when used in combination with Pomalidomide.
Mumps virus strain B level jeryl lynn live antigen
The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Pomalidomide.
Nabilone
Nabilone may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.
Nabumetone
The metabolism of Pomalidomide can be decreased when combined with Nabumetone.
Nalbuphine
The risk or severity of CNS depression can be increased when Nalbuphine is combined with Pomalidomide.
Naproxen
The metabolism of Pomalidomide can be decreased when combined with Naproxen.
Naratriptan
The risk or severity of CNS depression can be increased when Naratriptan is combined with Pomalidomide.
Neomycin
Pomalidomide may decrease the excretion rate of Neomycin which could result in a higher serum level.
Nifedipine
The metabolism of Pomalidomide can be decreased when combined with Nifedipine.
Nintedanib
The metabolism of Pomalidomide can be decreased when combined with Nintedanib.
Nitrous oxide
The risk or severity of CNS depression can be increased when Nitrous oxide is combined with Pomalidomide.
Norethisterone
The metabolism of Pomalidomide can be decreased when combined with Norethisterone.
Nortriptyline
The risk or severity of CNS depression can be increased when Nortriptyline is combined with Pomalidomide.
Nuvaxovid
The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Pomalidomide.
Obeticholic acid
The risk or severity of adverse effects can be increased when Obeticholic acid is combined with Pomalidomide.
Octreotide
The serum concentration of Pomalidomide can be increased when it is combined with Octreotide.
Olanzapine
The risk or severity of CNS depression can be increased when Olanzapine is combined with Pomalidomide.
Omadacycline
The serum concentration of Pomalidomide can be increased when it is combined with Omadacycline.
Ombitasvir
The serum concentration of Pomalidomide can be increased when it is combined with Ombitasvir.
Ondansetron
The risk or severity of CNS depression can be increased when Ondansetron is combined with Pomalidomide.
Opium
The risk or severity of CNS depression can be increased when Pomalidomide is combined with Opium.
Orphenadrine
Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Osilodrostat
The serum concentration of Pomalidomide can be increased when it is combined with Osilodrostat.
Osimertinib
The serum concentration of Pomalidomide can be decreased when it is combined with Osimertinib.
Oxazepam
The risk or severity of CNS depression can be increased when Oxazepam is combined with Pomalidomide.
Oxybuprocaine
The risk or severity of methemoglobinemia can be increased when Pomalidomide is combined with Oxybuprocaine.
Oxycodone
The risk or severity of CNS depression can be increased when Oxycodone is combined with Pomalidomide.
Oxymorphone
The risk or severity of CNS depression can be increased when Oxymorphone is combined with Pomalidomide.
Pacritinib
The serum concentration of Pomalidomide can be increased when it is combined with Pacritinib.
Palifermin
The therapeutic efficacy of Palifermin can be decreased when used in combination with Pomalidomide.
Palonosetron
The risk or severity of CNS depression can be increased when Palonosetron is combined with Pomalidomide.
Pamidronic acid
The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Pomalidomide is combined with Pamidronic acid.
Pancuronium
The risk or severity of CNS depression can be increased when Pancuronium is combined with Pomalidomide.
Paritaprevir
The serum concentration of Pomalidomide can be increased when it is combined with Paritaprevir.
Paroxetine
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Paroxetine.
Penciclovir
The metabolism of Pomalidomide can be decreased when combined with Penciclovir.
Pentazocine
The risk or severity of CNS depression can be increased when Pentazocine is combined with Pomalidomide.
Pentoxifylline
The metabolism of Pomalidomide can be decreased when combined with Pentoxifylline.
Perampanel
Perampanel may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.
Pergolide
The risk or severity of CNS depression can be increased when Pergolide is combined with Pomalidomide.
Perphenazine
The risk or severity of CNS depression can be increased when Perphenazine is combined with Pomalidomide.
Phenelzine
The risk or severity of CNS depression can be increased when Phenelzine is combined with Pomalidomide.
Phenol
The risk or severity of methemoglobinemia can be increased when Pomalidomide is combined with Phenol.
Pimavanserin
The metabolism of Pomalidomide can be decreased when combined with Pimavanserin.
Pindolol
The risk or severity of CNS depression can be increased when Pindolol is combined with Pomalidomide.
Pitolisant
The serum concentration of Pomalidomide can be decreased when it is combined with Pitolisant.
Plazomicin
Pomalidomide may decrease the excretion rate of Plazomicin which could result in a higher serum level.
Pramipexole
Pomalidomide may increase the sedative activities of Pramipexole.
Pramocaine
The risk or severity of methemoglobinemia can be increased when Pomalidomide is combined with Pramocaine.
Prasterone
The metabolism of Pomalidomide can be decreased when combined with Prasterone.
Pravastatin
The serum concentration of Pomalidomide can be increased when it is combined with Pravastatin.
Praziquantel
The metabolism of Pomalidomide can be decreased when combined with Praziquantel.
Pregabalin
The therapeutic efficacy of Pomalidomide can be increased when used in combination with Pregabalin.
Pretomanid
The serum concentration of Pomalidomide can be increased when it is combined with Pretomanid.
Prilocaine
The risk or severity of methemoglobinemia can be increased when Pomalidomide is combined with Prilocaine.
Procainamide
Pomalidomide may decrease the excretion rate of Procainamide which could result in a higher serum level.
Procaine
The risk or severity of methemoglobinemia can be increased when Pomalidomide is combined with Procaine.
Prochlorperazine
The risk or severity of CNS depression can be increased when Prochlorperazine is combined with Pomalidomide.
Promethazine
The risk or severity of CNS depression can be increased when Promethazine is combined with Pomalidomide.
Proparacaine
The risk or severity of methemoglobinemia can be increased when Pomalidomide is combined with Proparacaine.
Propranolol
The metabolism of Pomalidomide can be decreased when combined with Propranolol.
Protriptyline
The risk or severity of CNS depression can be increased when Protriptyline is combined with Pomalidomide.
Pyrantel
The risk or severity of CNS depression can be increased when Pomalidomide is combined with Pyrantel.
Quazepam
The risk or severity of CNS depression can be increased when Quazepam is combined with Pomalidomide.
Quetiapine
The risk or severity of CNS depression can be increased when Quetiapine is combined with Pomalidomide.
Quinidine
The serum concentration of Pomalidomide can be increased when it is combined with Quinidine.
Rabies immune globulin, human
The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Pomalidomide.
Rabies virus inactivated antigen, A
The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Pomalidomide.
Rabies virus inactivated antigen, B
The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Pomalidomide.
Ramelteon
The risk or severity of CNS depression can be increased when Ramelteon is combined with Pomalidomide.
Ranitidine
The metabolism of Pomalidomide can be decreased when combined with Ranitidine.
Ranolazine
The serum concentration of Pomalidomide can be increased when it is combined with Ranolazine.
Rasagiline
The risk or severity of CNS depression can be increased when Rasagiline is combined with Pomalidomide.
Relugolix
The serum concentration of Pomalidomide can be increased when it is combined with Relugolix.
Remifentanil
The risk or severity of CNS depression can be increased when Remifentanil is combined with Pomalidomide.
Remimazolam
The risk or severity of CNS depression can be increased when Pomalidomide is combined with Remimazolam.
Repotrectinib
The serum concentration of Pomalidomide can be decreased when it is combined with Repotrectinib.
Respiratory syncytial virus vaccine, adjuvanted
The therapeutic efficacy of GSK-3844766A can be decreased when used in combination with Pomalidomide.
Revefenacin
The serum concentration of Pomalidomide can be increased when it is combined with Revefenacin.
Ribociclib
The serum concentration of Pomalidomide can be increased when it is combined with Ribociclib.
Riluzole
The risk or severity of CNS depression can be increased when Riluzole is combined with Pomalidomide.
Rimegepant
The serum concentration of Pomalidomide can be increased when it is combined with Rimegepant.
Riociguat
The serum concentration of Pomalidomide can be increased when it is combined with Riociguat.
Risedronic acid
The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Pomalidomide is combined with Risedronic acid.
Risperidone
The risk or severity of CNS depression can be increased when Risperidone is combined with Pomalidomide.
Ritlecitinib
The serum concentration of Pomalidomide can be increased when it is combined with Ritlecitinib.
Ritonavir
The serum concentration of Pomalidomide can be increased when it is combined with Ritonavir.
Rivaroxaban
The serum concentration of Pomalidomide can be increased when it is combined with Rivaroxaban.
Rocuronium
The risk or severity of CNS depression can be increased when Rocuronium is combined with Pomalidomide.
Romidepsin
The serum concentration of Pomalidomide can be increased when it is combined with Romidepsin.
Ropeginterferon alfa-2b
The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Pomalidomide.
Ropinirole
Pomalidomide may increase the sedative activities of Ropinirole.
Ropivacaine
The risk or severity of methemoglobinemia can be increased when Pomalidomide is combined with Ropivacaine.
Rosuvastatin
The metabolism of Pomalidomide can be decreased when combined with Rosuvastatin.
Rotavirus vaccine
The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Pomalidomide.
Rotigotine
Pomalidomide may increase the sedative activities of Rotigotine.
Rucaparib
The metabolism of Pomalidomide can be decreased when combined with Rucaparib.
Rufinamide
The risk or severity of adverse effects can be increased when Rufinamide is combined with Pomalidomide.
Safinamide
The risk or severity of CNS depression can be increased when Safinamide is combined with Pomalidomide.
Samidorphan
The risk or severity of CNS depression can be increased when Pomalidomide is combined with Samidorphan.
Satralizumab
The serum concentration of Pomalidomide can be decreased when it is combined with Satralizumab.
Scopolamine
The risk or severity of CNS depression can be increased when Scopolamine is combined with Pomalidomide.
Selegiline
The risk or severity of CNS depression can be increased when Selegiline is combined with Pomalidomide.
Selexipag
The serum concentration of Pomalidomide can be increased when it is combined with Selexipag.
Selumetinib
The metabolism of Selumetinib can be decreased when combined with Pomalidomide.
Sertraline
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Sertraline.
Sevoflurane
The risk or severity of CNS depression can be increased when Sevoflurane is combined with Pomalidomide.
Silodosin
The serum concentration of Pomalidomide can be increased when it is combined with Silodosin.
Sipuleucel-T
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pomalidomide.
Sitagliptin
The serum concentration of Pomalidomide can be increased when it is combined with Sitagliptin.
Sofosbuvir
The serum concentration of Pomalidomide can be increased when it is combined with Sofosbuvir.
Solriamfetol
The risk or severity of CNS depression can be increased when Pomalidomide is combined with Solriamfetol.
Streptomycin
Pomalidomide may decrease the excretion rate of Streptomycin which could result in a higher serum level.
Succinylcholine
The risk or severity of CNS depression can be increased when Succinylcholine is combined with Pomalidomide.
Sufentanil
The risk or severity of CNS depression can be increased when Sufentanil is combined with Pomalidomide.
Sulfamethoxazole
The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Pomalidomide.
Sumatriptan
The risk or severity of CNS depression can be increased when Sumatriptan is combined with Pomalidomide.
Suvorexant
Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Pomalidomide.
Talazoparib
The serum concentration of Talazoparib can be increased when it is combined with Pomalidomide.
Tapentadol
Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.
Tasimelteon
The metabolism of Pomalidomide can be decreased when combined with Tasimelteon.
Tazemetostat
The metabolism of Pomalidomide can be decreased when combined with Tazemetostat.
Technetium Tc-99m sestamibi
The serum concentration of Pomalidomide can be increased when it is combined with Technetium Tc-99m sestamibi.
Telotristat ethyl
The serum concentration of Pomalidomide can be decreased when it is combined with Telotristat ethyl.
Temazepam
The risk or severity of CNS depression can be increased when Temazepam is combined with Pomalidomide.
Tenofovir alafenamide
The serum concentration of Tenofovir alafenamide can be increased when it is combined with Pomalidomide.
Tenofovir disoproxil
The serum concentration of Pomalidomide can be increased when it is combined with Tenofovir disoproxil.
Teriflunomide
The serum concentration of Pomalidomide can be decreased when it is combined with Teriflunomide.
Tetracaine
The risk or severity of methemoglobinemia can be increased when Pomalidomide is combined with Tetracaine.
Tezacaftor
The serum concentration of Pomalidomide can be increased when it is combined with Tezacaftor.
Thioridazine
The risk or severity of CNS depression can be increased when Thioridazine is combined with Pomalidomide.
Thiothixene
The risk or severity of CNS depression can be increased when Thiothixene is combined with Pomalidomide.
Tiagabine
The risk or severity of CNS depression can be increased when Tiagabine is combined with Pomalidomide.
Tick-borne encephalitis vaccine (whole virus, inactivated)
The therapeutic efficacy of Tick-borne encephalitis vaccine (whole virus, inactivated) can be decreased when used in combination with Pomalidomide.
Tivozanib
The serum concentration of Pomalidomide can be increased when it is combined with Tivozanib.
Tobramycin
Pomalidomide may decrease the excretion rate of Tobramycin which could result in a higher serum level.
Tofacitinib
Pomalidomide may increase the immunosuppressive activities of Tofacitinib.
Tolcapone
The risk or severity of CNS depression can be increased when Tolcapone is combined with Pomalidomide.
Tolvaptan
The serum concentration of Pomalidomide can be increased when it is combined with Tolvaptan.
Tovorafenib
The metabolism of Pomalidomide can be increased when combined with Tovorafenib.
Tramadol
The risk or severity of CNS depression can be increased when Pomalidomide is combined with Tramadol.
Tranylcypromine
The risk or severity of CNS depression can be increased when Tranylcypromine is combined with Pomalidomide.
Trastuzumab
The risk or severity of neutropenia can be increased when Trastuzumab is combined with Pomalidomide.
Triamterene
The metabolism of Pomalidomide can be decreased when combined with Triamterene.
Triazolam
The risk or severity of CNS depression can be increased when Triazolam is combined with Pomalidomide.
Trifluoperazine
The risk or severity of CNS depression can be increased when Trifluoperazine is combined with Pomalidomide.
Trimethobenzamide
The risk or severity of CNS depression can be increased when Trimethobenzamide is combined with Pomalidomide.
Trimipramine
The risk or severity of CNS depression can be increased when Trimipramine is combined with Pomalidomide.
Triprolidine
The risk or severity of CNS depression can be increased when Triprolidine is combined with Pomalidomide.
Tryptophan
The risk or severity of CNS depression can be increased when Tryptophan is combined with Pomalidomide.
Tucatinib
Tucatinib may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Typhoid vaccine
The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Pomalidomide.
Typhoid Vi polysaccharide vaccine
The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Pomalidomide.
Ublituximab
The risk or severity of infection can be increased when Ublituximab is combined with Pomalidomide.
Ubrogepant
The serum concentration of Pomalidomide can be increased when it is combined with Ubrogepant.
Umeclidinium
The serum concentration of Pomalidomide can be increased when it is combined with Umeclidinium.
Vancomycin
Pomalidomide may decrease the excretion rate of Vancomycin which could result in a higher serum level.
Varicella zoster vaccine (recombinant)
The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Pomalidomide.
Vecuronium
The risk or severity of CNS depression can be increased when Vecuronium is combined with Pomalidomide.
Vemurafenib
The serum concentration of Pomalidomide can be increased when it is combined with Vemurafenib.
Venlafaxine
The risk or severity of CNS depression can be increased when Venlafaxine is combined with Pomalidomide.
Vigabatrin
The risk or severity of CNS depression can be increased when Vigabatrin is combined with Pomalidomide.
Vilazodone
The risk or severity of CNS depression can be increased when Vilazodone is combined with Pomalidomide.
Vimseltinib
The serum concentration of Pomalidomide can be increased when it is combined with Vimseltinib.
Voclosporin
The serum concentration of Pomalidomide can be increased when it is combined with Voclosporin.
Vortioxetine
The risk or severity of CNS depression can be increased when Pomalidomide is combined with Vortioxetine.
Xanomeline
The serum concentration of Pomalidomide can be increased when it is combined with Xanomeline.
Zaleplon
The risk or severity of CNS depression can be increased when Zaleplon is combined with Pomalidomide.
Ziconotide
The risk or severity of CNS depression can be increased when Ziconotide is combined with Pomalidomide.
Ziprasidone
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Ziprasidone.
Zoledronic acid
The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Pomalidomide is combined with Zoledronic acid.
Zolmitriptan
The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Pomalidomide.
Zolpidem
Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Zuranolone
The risk or severity of CNS depression can be increased when Zuranolone is combined with Pomalidomide.
Abacavir
Abacavir may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Abiraterone
The serum concentration of Pomalidomide can be increased when it is combined with Abiraterone.
Abrocitinib
The serum concentration of Pomalidomide can be increased when it is combined with Abrocitinib.
Aceclofenac
Aceclofenac may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Acetylsalicylic acid
The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Pomalidomide.
Aclidinium
Aclidinium may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Acrivastine
Pomalidomide may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Adefovir dipivoxil
Adefovir dipivoxil may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Albuterol
Salbutamol may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Albutrepenonacog alfa
Pomalidomide may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
Allogeneic processed thymus tissue
The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Pomalidomide.
Almasilate
Pomalidomide may decrease the excretion rate of Almasilate which could result in a higher serum level.
Alogliptin
Alogliptin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Alteplase
The risk or severity of bleeding can be increased when Alteplase is combined with Pomalidomide.
Amantadine
Amantadine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Amiloride
Amiloride may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.
Ammonium chloride
Ammonium chloride may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Amoxicillin
Amoxicillin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Amphetamine
Amphetamine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Amphotericin B
Amphotericin B may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Ampicillin
Ampicillin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Anthrax vaccine
The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Pomalidomide.
Antithrombin Alfa
The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Pomalidomide.
Antithrombin III human
Pomalidomide may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.
Arformoterol
Arformoterol may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Argatroban
The risk or severity of bleeding can be increased when Argatroban is combined with Pomalidomide.
Astaxanthin
The risk or severity of bleeding can be increased when Astaxanthin is combined with Pomalidomide.
Atomoxetine
Atomoxetine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Auranofin
Auranofin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Azelaic acid
Azelaic acid may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Aztreonam
Aztreonam may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Bacitracin
Bacitracin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Baclofen
Baclofen may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.
Balsalazide
Balsalazide may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Bendroflumethiazide
Bendroflumethiazide may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.
Benzatropine
Benzatropine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Benznidazole
Pomalidomide may decrease the excretion rate of Benznidazole which could result in a higher serum level.
Bepotastine
Bepotastine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Bicisate
Pomalidomide may decrease the excretion rate of Bicisate which could result in a higher serum level.
Bismuth subgallate
Pomalidomide may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level.
Bivalirudin
The risk or severity of bleeding can be increased when Bivalirudin is combined with Pomalidomide.
Bumetanide
Bumetanide may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Cangrelor
The risk or severity of bleeding can be increased when Cangrelor is combined with Pomalidomide.
Caplacizumab
The risk or severity of bleeding can be increased when Caplacizumab is combined with Pomalidomide.
Carbidopa
Carbidopa may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Cefaclor
Cefaclor may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Cefadroxil
Cefadroxil may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Cefazolin
Cefazolin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Cefdinir
Cefdinir may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Cefditoren
Cefditoren may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Cefepime
Cefepime may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Cefotaxime
Cefotaxime may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Cefotetan
Cefotetan may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Cefoxitin
Cefoxitin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Cefpodoxime
Cefpodoxime may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Cefprozil
Cefprozil may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Ceftaroline fosamil
Ceftaroline fosamil may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Ceftazidime
Ceftazidime may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Ceftibuten
Ceftibuten may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Ceftizoxime
Ceftizoxime may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Ceftolozane
Pomalidomide may decrease the excretion rate of Ceftolozane which could result in a higher serum level.
Ceftriaxone
Ceftriaxone may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Cefuroxime
Cefuroxime may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Celecoxib
Celecoxib may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Cevimeline
Cevimeline may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Chloroquine
Chloroquine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Chlorothiazide
Chlorothiazide may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.
Chlorthalidone
Chlorthalidone may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.
Choline salicylate
Pomalidomide may decrease the excretion rate of Choline salicylate which could result in a higher serum level.
Chondroitin sulfate
Pomalidomide may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.
Chromic chloride
Pomalidomide may decrease the excretion rate of Chromic chloride which could result in a higher serum level.
Chromium
Pomalidomide may decrease the excretion rate of Chromium which could result in a higher serum level.
Chromium nicotinate
Pomalidomide may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level.
Cidofovir
Cidofovir may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Cladribine
Pomalidomide may increase the immunosuppressive activities of Cladribine.
Clove oil
Pomalidomide may decrease the excretion rate of Clove oil which could result in a higher serum level.
Colistimethate
Colistimethate may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Dalfampridine
Dalfampridine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Dalteparin
The risk or severity of bleeding can be increased when Dalteparin is combined with Pomalidomide.
Daridorexant
The risk or severity of CNS depression can be increased when Pomalidomide is combined with Daridorexant.
Deferasirox
The serum concentration of Pomalidomide can be increased when it is combined with Deferasirox.
Deferiprone
Deferiprone may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Defibrotide
The risk or severity of bleeding can be increased when Defibrotide is combined with Pomalidomide.
Delafloxacin
Pomalidomide may decrease the excretion rate of Delafloxacin which could result in a higher serum level.
Desmopressin
Desmopressin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Deutetrabenazine
Pomalidomide may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.
Dexpanthenol
Pomalidomide may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.
Dextran
Pomalidomide may decrease the excretion rate of Dextran which could result in a higher serum level.
Diatrizoate
Diatrizoate may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Diclofenamide
Diclofenamide may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.
Dicyclomine
Dicyclomine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Didanosine
Didanosine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Dienogest
Pomalidomide may decrease the excretion rate of Dienogest which could result in a higher serum level.
Diflunisal
Diflunisal may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Dimercaprol
Dimercaprol may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Dipyridamole
The risk or severity of bleeding can be increased when Dipyridamole is combined with Pomalidomide.
DL-Methylephedrine
Pomalidomide may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level.
Dobutamine
Dobutamine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Dopamine
Dopamine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Doxycycline
Doxycycline may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Droxidopa
Droxidopa may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Edetic acid
The risk or severity of bleeding can be increased when Edetic acid is combined with Pomalidomide.
Edrophonium
Edrophonium may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Enalaprilat
Pomalidomide may decrease the excretion rate of Enalaprilat which could result in a higher serum level.
Enoxaparin
The risk or severity of bleeding can be increased when Enoxaparin is combined with Pomalidomide.
Eplerenone
Eplerenone may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.
Epoprostenol
The risk or severity of bleeding can be increased when Epoprostenol is combined with Pomalidomide.
Eptifibatide
The risk or severity of bleeding can be increased when Eptifibatide is combined with Pomalidomide.
Ertapenem
Ertapenem may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Etacrynic acid
Etacrynic acid may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Ethenzamide
Ethenzamide may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Etodolac
Etodolac may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Etonogestrel
Etonogestrel may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Eucalyptus oil
Pomalidomide may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Evening primrose oil
Pomalidomide may decrease the excretion rate of Evening primrose oil which could result in a higher serum level.
Fenofibric acid
Pomalidomide may decrease the excretion rate of Fenofibric acid which could result in a higher serum level.
Fenoldopam
Fenoldopam may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Fenoprofen
Fenoprofen may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Fesoterodine
Fesoterodine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Finerenone
Finerenone may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.
Flavoxate
Flavoxate may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Florbetaben F-18
Pomalidomide may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.
Florbetapir F-18
Pomalidomide may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.
Fludeoxyglucose (18F)
Pomalidomide may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.
Flumazenil
Flumazenil may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Flurbiprofen
Flurbiprofen may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Folic acid
Folic acid may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Fomepizole
Fomepizole may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Fondaparinux
Fondaparinux may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Foscarnet
Foscarnet may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Fosfomycin
Fosfomycin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Fosinopril
Fosinopril may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Furosemide
Furosemide may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Gadobenic acid
Gadobenic acid may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Gadodiamide
Gadodiamide may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Gadofosveset trisodium
Gadofosveset trisodium may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Gadoteric acid
Pomalidomide may decrease the excretion rate of Gadoteric acid which could result in a higher serum level.
Gadoteridol
Gadoteridol may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Ganciclovir
Ganciclovir may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Glipizide
Glipizide may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Golodirsen
Pomalidomide may decrease the excretion rate of Golodirsen which could result in a higher serum level.
Goserelin
Goserelin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Heparin
The risk or severity of bleeding can be increased when Heparin is combined with Pomalidomide.
Hydrochlorothiazide
Hydrochlorothiazide may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Hydroflumethiazide
Hydroflumethiazide may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.
Hydroxocobalamin
Hydroxocobalamin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Hydroxyethyl Starch
Pomalidomide may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.
Ibuprofen
Ibuprofen may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Ibutilide
Ibutilide may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Icatibant
Icatibant may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Icosapent
Icosapent may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Icosapent ethyl
The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Pomalidomide.
Idarucizumab
Pomalidomide may decrease the excretion rate of Idarucizumab which could result in a higher serum level.
Indapamide
Indapamide may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Indigotindisulfonic acid
Pomalidomide may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.
Inebilizumab
The risk or severity of infection can be increased when Pomalidomide is combined with Inebilizumab.
Inositol
Pomalidomide may decrease the excretion rate of Inositol which could result in a higher serum level.
Inotersen
Inotersen may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Iobenguane sulfate I-123
Pomalidomide may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.
Iodixanol
Iodixanol may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Ioflupane I-123
Ioflupane I-123 may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Iopromide
Pomalidomide may decrease the excretion rate of Iopromide which could result in a higher serum level.
Iothalamic acid
Pomalidomide may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.
Ioversol
Pomalidomide may decrease the excretion rate of Ioversol which could result in a higher serum level.
Ipecac
Pomalidomide may decrease the excretion rate of Ipecac which could result in a higher serum level.
Ipilimumab
Ipilimumab may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Isosorbide
Isosorbide may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.
Isosorbide mononitrate
Isosorbide mononitrate may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Isosulfan blue
Pomalidomide may decrease the excretion rate of Isosulfan blue which could result in a higher serum level.
Isotretinoin
Isotretinoin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Ixazomib
Pomalidomide may decrease the excretion rate of Ixazomib which could result in a higher serum level.
Ketoprofen
Ketoprofen may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Ketorolac
Ketorolac may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
L-Acetylleucine
The serum concentration of Pomalidomide can be increased when it is combined with L-Acetylleucine.
Labetalol
Labetalol may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Lamivudine
Lamivudine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Lazertinib
The metabolism of Pomalidomide can be decreased when combined with Lazertinib.
Lenacapavir
The metabolism of Pomalidomide can be decreased when combined with Lenacapavir.
Leuprolide
Leuprolide may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Levocarnitine
Levocarnitine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Levofloxacin
Levofloxacin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Levomilnacipran
Pomalidomide may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Levosalbutamol
Pomalidomide may decrease the excretion rate of Levosalbutamol which could result in a higher serum level.
Liothyronine
Liothyronine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Lisinopril
Lisinopril may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Lithium citrate
Lithium citrate may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Lixisenatide
Pomalidomide may decrease the excretion rate of Lixisenatide which could result in a higher serum level.
Lubiprostone
Lubiprostone may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Macitentan
Pomalidomide may decrease the excretion rate of Macitentan which could result in a higher serum level.
Magnesium carbonate
Pomalidomide may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.
Magnesium chloride
Pomalidomide may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.
Magnesium hydroxide
Pomalidomide may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.
Magnesium salicylate
Magnesium salicylate may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Magnesium trisilicate
Pomalidomide may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level.
Mavorixafor
The metabolism of Pomalidomide can be decreased when combined with Mavorixafor.
Mecamylamine
Mecamylamine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Meclofenamic acid
Meclofenamic acid may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Megestrol acetate
Megestrol acetate may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Memantine
Memantine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Meropenem
Meropenem may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Mesalazine
Mesalazine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Metamfetamine
Metamfetamine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Metformin
Metformin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Methazolamide
Methazolamide may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.
Methyldopa
Methyldopa may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Methylnaltrexone
Methylnaltrexone may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Methyltestosterone
Methyltestosterone may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Metolazone
Metolazone may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Metoprolol
Metoprolol may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Metreleptin
The metabolism of Pomalidomide can be increased when combined with Metreleptin.
Migalastat
Migalastat may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Milrinone
Milrinone may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Minocycline
Minocycline may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.
Mitapivat
The metabolism of Pomalidomide can be increased when combined with Mitapivat.
Mosunetuzumab
The metabolism of Pomalidomide can be decreased when combined with Mosunetuzumab.
N-acetyltyrosine
Pomalidomide may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.
Nadolol
Nadolol may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Naldemedine
Pomalidomide may decrease the excretion rate of Naldemedine which could result in a higher serum level.
Nalmefene
Nalmefene may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Naloxone
Naloxone may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Nateglinide
Nateglinide may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Nedocromil
Nedocromil may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Nilutamide
Nilutamide may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Nisoldipine
Nisoldipine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Nitric Oxide
Nitric Oxide may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Nitrofurantoin
Nitrofurantoin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Nitroprusside
Nitroprusside may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Octinoxate
Pomalidomide may decrease the excretion rate of Octinoxate which could result in a higher serum level.
Olsalazine
Olsalazine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Omaveloxolone
The serum concentration of Pomalidomide can be decreased when it is combined with Omaveloxolone.
Oseltamivir
Oseltamivir may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Oxacillin
Oxacillin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Oxaprozin
Oxaprozin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Oxybenzone
Oxybenzone may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Oxyquinoline
Pomalidomide may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.
Pantoprazole
Pantoprazole may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Parecoxib
Parecoxib may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Paromomycin
Paromomycin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Peginterferon alfa-2b
The serum concentration of Pomalidomide can be increased when it is combined with Peginterferon alfa-2b.
Pentamidine
Pentamidine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Pentetic acid
Pomalidomide may decrease the excretion rate of Pentetic acid which could result in a higher serum level.
Pentosan polysulfate
The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Pomalidomide.
Perindopril
Perindopril may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Permethrin
Permethrin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Phenazopyridine
Phenazopyridine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Phosphoric acid
Pomalidomide may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.
Phylloquinone
Phylloquinone may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Picosulfuric acid
Pomalidomide may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level.
Piperacillin
Piperacillin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Piroxicam
Piroxicam may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Plerixafor
Plerixafor may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Polythiazide
Polythiazide may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.
Potassium
Potassium may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.
Potassium acetate
Pomalidomide may decrease the excretion rate of Potassium acetate which could result in a higher serum level.
Potassium bicarbonate
Pomalidomide may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level.
Potassium cation
Potassium cation may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Potassium chloride
Potassium chloride may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Potassium citrate
Potassium citrate may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.
Potassium nitrate
Pomalidomide may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.
Potassium sulfate
Pomalidomide may decrease the excretion rate of Potassium sulfate which could result in a higher serum level.
Pralidoxime
Pralidoxime may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Prasugrel
The risk or severity of bleeding can be increased when Prasugrel is combined with Pomalidomide.
Procaine benzylpenicillin
Pomalidomide may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.
Propantheline
Propantheline may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Propyphenazone
Propyphenazone may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Protein C
The risk or severity of bleeding can be increased when Protein C is combined with Pomalidomide.
Protein S human
The risk or severity of bleeding can be increased when Protein S human is combined with Pomalidomide.
Prucalopride
Prucalopride may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Pyrazinamide
Pyrazinamide may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Pyridoxine
Pyridoxine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Rabeprazole
Rabeprazole may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Resorcinol
Pomalidomide may decrease the excretion rate of Resorcinol which could result in a higher serum level.
Resveratrol
The risk or severity of bleeding can be increased when Resveratrol is combined with Pomalidomide.
Ribavirin
Ribavirin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Rilzabrutinib
The metabolism of Pomalidomide can be decreased when combined with Rilzabrutinib.
Rizatriptan
Rizatriptan may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Roflumilast
Roflumilast may increase the immunosuppressive activities of Pomalidomide.
Rosiglitazone
Rosiglitazone may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Sacubitril
Pomalidomide may decrease the excretion rate of Sacubitril which could result in a higher serum level.
Salicylamide
Salicylamide may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Salicylic acid
Salicylic acid may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Salmon calcitonin
Salmon calcitonin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Salsalate
Salsalate may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Saxagliptin
Saxagliptin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Selenious acid
Pomalidomide may decrease the excretion rate of Selenious acid which could result in a higher serum level.
Selenium
Pomalidomide may decrease the excretion rate of Selenium which could result in a higher serum level.
Sodium acetate
Pomalidomide may decrease the excretion rate of Sodium acetate which could result in a higher serum level.
Sodium citrate
The risk or severity of bleeding can be increased when Sodium citrate is combined with Pomalidomide.
Sodium fluoride
Pomalidomide may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.
Sodium sulfate
Pomalidomide may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.
Somatrogon
The metabolism of Pomalidomide can be increased when combined with Somatrogon.
Sorbitol
Sorbitol may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Spironolactone
Spironolactone may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.
Sucralfate
Sucralfate may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Sulbactam
Pomalidomide may decrease the excretion rate of Sulbactam which could result in a higher serum level.
Sulfadiazine
Sulfadiazine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Sulindac
Sulindac may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Suzetrigine
The metabolism of Pomalidomide can be increased when combined with Suzetrigine.
Synthetic Conjugated Estrogens, A
Pomalidomide may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level.
Synthetic Conjugated Estrogens, B
Pomalidomide may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level.
Tadalafil
Tadalafil may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Tamsulosin
Tamsulosin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Technetium Tc-99m exametazime
Pomalidomide may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.
Technetium Tc-99m pyrophosphate
Pomalidomide may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level.
Tedizolid phosphate
The risk or severity of myelosuppression can be increased when Pomalidomide is combined with Tedizolid phosphate.
Teduglutide
Teduglutide may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Telavancin
Telavancin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Tenecteplase
The risk or severity of bleeding can be increased when Tenecteplase is combined with Pomalidomide.
Terbutaline
Terbutaline may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Testosterone cypionate
Pomalidomide may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level.
Testosterone enanthate
Pomalidomide may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level.
Testosterone propionate
Testosterone propionate may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Testosterone undecanoate
Pomalidomide may decrease the excretion rate of Testosterone undecanoate which could result in a higher serum level.
Tetradecyl hydrogen sulfate (ester)
Pomalidomide may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.
Timolol
Timolol may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Tinidazole
Tinidazole may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Tinzaparin
The risk or severity of bleeding can be increased when Tinzaparin is combined with Pomalidomide.
Tiopronin
Tiopronin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Tiotropium
Tiotropium may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Tirofiban
The risk or severity of bleeding can be increased when Tirofiban is combined with Pomalidomide.
Tocopherol
Pomalidomide may decrease the excretion rate of Tocopherol which could result in a higher serum level.
Tocopherylquinone
The risk or severity of bleeding can be increased when Tocopherylquinone is combined with Pomalidomide.
Tolazamide
Tolazamide may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Tolmetin
Tolmetin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Tolterodine
Tolterodine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Torasemide
Torasemide may increase the excretion rate of Pomalidomide which could result in a lower serum level and potentially a reduction in efficacy.
Trametinib
Pomalidomide may decrease the excretion rate of Trametinib which could result in a higher serum level.
Triethylenetetramine
Triethylenetetramine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Trimethoprim
Trimethoprim may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Trimetrexate
Trimetrexate may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Trofinetide
The metabolism of Pomalidomide can be decreased when combined with Trofinetide.
Trolamine salicylate
Trolamine salicylate may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Troxerutin
The risk or severity of bleeding can be increased when Troxerutin is combined with Pomalidomide.
Urokinase
The risk or severity of bleeding can be increased when Urokinase is combined with Pomalidomide.
Vaborbactam
Pomalidomide may decrease the excretion rate of Vaborbactam which could result in a higher serum level.
Vadadustat
The serum concentration of Pomalidomide can be increased when it is combined with Vadadustat.
Valaciclovir
Valaciclovir may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Valbenazine
Pomalidomide may decrease the excretion rate of Valbenazine which could result in a higher serum level.
Valdecoxib
Valdecoxib may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Valganciclovir
Valganciclovir may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Varenicline
Varenicline may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Vibrio cholerae CVD 103-HgR strain live antigen
The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Pomalidomide.
Zanamivir
Zanamivir may decrease the excretion rate of Pomalidomide which could result in a higher serum level.